PeproMene Bio is a clinical-stage biotech company based in Irvine, California, dedicated to developing innovative immune therapies.

We are pioneering BAFF-R targeting CAR-T cell therapy, a novel approach to treating a broad range of B cell malignancies and autoimmune diseases. Our research is built upon a groundbreaking discovery by Dr. Larry Kwak’s team at MD Anderson Cancer Center and City of Hope National Medical Center, utilizing a unique antibody to target BAFF-R, an excellent potential target for B-cell cancers.

By overcoming the challenge of antigen loss, our therapies offer the potential to significantly improve patient outcomes and provide hope for individuals facing these challenging conditions. We are committed to advancing these therapies and collaborating with leading institutions to bring transformative treatments to patients in need.

PeproMene Bio is focused on developing innovative therapies to improve the lives of patients with cancer and immune disorders.

BAFF-R/CD3 Bispecific mAb | Pepromene Bio

Product description

Pepromene Bio Irvine, United States (US)

Price: N/A

Pepromene Bio
Irvine, United States (US)